Last updated on June 2019

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.


Brief description of study

The purpose of this phase 2 dose-ranging trial is to investigate the effects of FE 999302 on parameters influencing pregnancy rates in women undergoing Controlled Ovarian Stimulation (COS) with follitropin delta in a long gonadotropin releasing hormone (GnRH) agonist protocol.

Furthermore, the study intends:

  • To investigate the safety of FE 999302 in women undergoing COS with follitropin delta in a long GnRH agonist protocol.
  • To investigate the potential immunogenicity of FE 999302 in subjects undergoing COS with follitropin delta in a long GnRH agonist protocol.
  • To estimate the impact of body weight on FE 999302 exposure in subjects undergoing COS with follitropin delta in a long GnRH agonist protocol.

Clinical Study Identifier: NCT03564509

Find a site near you

Start Over

Rigshospitalet

Copenhagen, Denmark
  Connect »

Dansk Fertilitetsklinik

Frederiksberg, Denmark
2.14miles
  Connect »

Hvidovre Hospital

Hvidovre, Denmark
4.3miles
  Connect »